NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $0.87 -0.03 (-3.33%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.93 +0.06 (+7.36%) As of 11/13/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Marker Therapeutics Stock (NASDAQ:MRKR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Marker Therapeutics alerts:Sign Up Key Stats Today's Range$0.87▼$0.9350-Day Range$0.87▼$1.2852-Week Range$0.87▼$2.46Volume76,084 shsAverage Volume146,045 shsMarket Capitalization$14.50 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies. These candidates are investigational and remain in clinical development. Marker Therapeutics was formed in 2018 through a merger involving TapImmune and Marker Therapeutics, Inc.; TapImmune subsequently adopted the Marker Therapeutics name. The company is based in Houston, Texas, and its development work centers on advancing cell-based cancer treatments.AI Generated. May Contain Errors. Read More Marker Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreMRKR MarketRank™: 2.79539473684 of 5 starsMarker Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 444th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMarker Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMarker Therapeutics has a consensus price target of $10.00, representing about 1,049.4% upside from its current price of $0.87.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.64) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marker Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marker Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.12% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently increased by 61.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentMarker Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for MRKR on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of Marker Therapeutics is held by insiders.Percentage Held by Institutions22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRKR Stock News HeadlinesMarker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer StudyOctober 19, 2026 | rttnews.comMarker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic CancerOctober 19, 2026 | finance.yahoo.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 15 at 1:00 AM | Weiss Ratings (Ad)Marker Highlights Expanded Manufacturing Support For MT-601September 22, 2026 | rttnews.comMarker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced TherapiesSeptember 22, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)August 22, 2026 | theglobeandmail.comMarker Therapeutics Sets Date for 2026 Annual MeetingMay 19, 2026 | theglobeandmail.comMarker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comSee More Headlines MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $1.49 on January 1st, 2026. Since then, MRKR shares have decreased by 41.6% and is now trading at $0.87. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.16. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Viking Therapeutics (VKTX), AT&T (T), Tesla (TSLA) and Netflix (NFLX). Company Calendar Last Earnings8/14/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MRKR's financial health is in the Yellow zone, according to TradeSmith. MRKR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MRKR CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees5Year Founded2018Price Target and Rating Average Price Target for Marker Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+1,049.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.16 million Net MarginsN/A Pretax Margin-373.37% Return on Equity-56.96% Return on Assets-47.82% Debt Debt-to-Equity RatioN/A Current Ratio6.03 Quick Ratio6.03 Sales & Book Value Annual Sales$3.55 million Price / Sales4.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book0.86Miscellaneous Outstanding Shares16,670,000Free Float15,723,000Market Cap$14.50 million OptionableNot Optionable Beta1.65 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MRKR) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.